Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chiral Chromatographic Analysis of Amino Acids with Pre-column Derivatization by o-Phthalaldehyde: Improving the Determination of Enantiomers Using Ion-Pair Reagents.

Acta naturae·2026
Same author

Bcl-2 modifying factor (Bmf): "a mysterious stranger" in the Bcl-2 family proteins.

Cell death and differentiation·2025
Same author

BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition.

Apoptosis : an international journal on programmed cell death·2024
Same author

[Stochastic Packaging of Cas Proteins into Exosomes].

Molekuliarnaia biologiia·2024
Same author

Methionine gamma lyase fused with S3 domain VGF forms octamers and adheres to tumor cells via binding to EGFR.

Biochemical and biophysical research communications·2023
Same author

Search for Inhibitors of Mycobacterium tuberculosis Transketolase in a Series of Sulfo-Substituted Compounds.

Acta naturae·2023

Related Experiment Video

Updated: Jul 7, 2026

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

12.3K

7-Methylguanine Inhibits Colon Cancer Growth in Vivo.

K I Kirsanov1,2, T I Fetisov1, E E Antoshina1

  • 1Blokhin National Medical Research Center of Oncology, Institute of Carcinogenesis, Moscow, 115478 Russian Federation.

Acta Naturae
|August 27, 2024
PubMed
Summary

7-Methylguanine (7-MG) inhibits key enzymes for cancer cell growth. This study shows 7-MG effectively penetrates tumors and suppresses colon adenocarcinoma in preclinical models.

Keywords:
BALB/c micecolon cancerinhibitormethylguaninepoly(ADP-ribose) polymerase 1tRNA-guanine transglycosylase

More Related Videos

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

10.0K
HPLC Measurement of the DNA Oxidation Biomarker, 8-oxo-7,8-dihydro-2’-deoxyguanosine, in Cultured Cells and Animal Tissues
14:12

HPLC Measurement of the DNA Oxidation Biomarker, 8-oxo-7,8-dihydro-2’-deoxyguanosine, in Cultured Cells and Animal Tissues

Published on: August 1, 2015

27.1K

Related Experiment Videos

Last Updated: Jul 7, 2026

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

12.3K
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

10.0K
HPLC Measurement of the DNA Oxidation Biomarker, 8-oxo-7,8-dihydro-2’-deoxyguanosine, in Cultured Cells and Animal Tissues
14:12

HPLC Measurement of the DNA Oxidation Biomarker, 8-oxo-7,8-dihydro-2’-deoxyguanosine, in Cultured Cells and Animal Tissues

Published on: August 1, 2015

27.1K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • 7-Methylguanine (7-MG) is a natural inhibitor of poly(ADP-ribose) polymerase 1 and tRNA-guanine transglycosylase.
  • Enzymatic activity of these targets is crucial for cancer cell proliferation.
  • Preclinical studies have established the safety and intragastric administration regimen of 7-MG in mice.

Purpose of the Study:

  • To investigate the pharmacological activity of 7-Methylguanine (7-MG).
  • To evaluate the efficacy of 7-MG in suppressing tumor growth in vivo.
  • To assess tumor penetration of 7-MG.

Main Methods:

  • Pharmacological activity assessment in BALB/c and BALB/c nude mice models.
  • Transplanted tumor models including Akatol colon adenocarcinoma and human HCT116 xenografts.
  • Evaluation of 7-MG tumor tissue penetration and growth suppression.

Main Results:

  • 7-Methylguanine (7-MG) demonstrates effective penetration into tumor tissues.
  • 7-MG significantly suppresses the growth of colon adenocarcinoma in the Akatol model.
  • 7-MG also inhibits the growth of human HCT116 cells in a xenograft model.

Conclusions:

  • 7-Methylguanine (7-MG) exhibits significant anti-tumor activity against colon adenocarcinoma.
  • The findings support the potential of 7-MG as a therapeutic agent for colon cancer.
  • Further research into 7-MG's mechanism and clinical application is warranted.